Christine H Chung

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Impact of HPV-related head and neck cancer in clinical trials: opportunity to translate scientific insight into personalized care
    Christine H Chung
    Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1 Room 344, Baltimore, MD 21231 1000, USA
    Otolaryngol Clin North Am 45:795-806. 2012
  2. ncbi Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 81:331-8. 2011
  3. ncbi Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)
    Christine H Chung
    Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB 1 Room 344, Baltimore, MD 21231 1000, USA
    J Clin Oncol 29:1326-34. 2011
  4. ncbi Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 24:4170-6. 2006
  5. ncbi Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
  6. ncbi Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways
    Robbert J C Slebos
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Int J Cancer 132:568-79. 2013
  7. ncbi Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
  8. ncbi Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
  9. ncbi Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
  10. ncbi Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer
    Brian Bierie
    Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
    J Clin Invest 119:1571-82. 2009

Detail Information

Publications41

  1. ncbi Impact of HPV-related head and neck cancer in clinical trials: opportunity to translate scientific insight into personalized care
    Christine H Chung
    Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1 Room 344, Baltimore, MD 21231 1000, USA
    Otolaryngol Clin North Am 45:795-806. 2012
    ..This review discusses these research issues...
  2. ncbi Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 81:331-8. 2011
    ..We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC)...
  3. ncbi Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)
    Christine H Chung
    Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB 1 Room 344, Baltimore, MD 21231 1000, USA
    J Clin Oncol 29:1326-34. 2011
    ..Additional proteins known to be modulated by Hh signaling, including beta-catenin (CTNNB1) and epidermal growth factor receptor (EGFR), were also assessed to determine the correlation among these distinct signaling pathways...
  4. ncbi Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 24:4170-6. 2006
    ..A better understanding of the EGFR pathway may improve the use of EGFR inhibitors in HNSCC...
  5. ncbi Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
    ..This phase 2 trial evaluated the tolerability and clinical efficacy of the combination of oxaliplatin and pemetrexed as an induction chemotherapy regimen in locally advanced head and neck squamous cell carcinoma (HNSCC)...
  6. ncbi Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways
    Robbert J C Slebos
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Int J Cancer 132:568-79. 2013
    ..These identified proteomic changes reveal novel driving molecular pathways for HPV+ and HPV- OPCs that may be pertinent in therapeutic strategies and outcomes of OPC...
  7. ncbi Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
    ..In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG...
  8. ncbi Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  9. ncbi Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
    ....
  10. ncbi Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer
    Brian Bierie
    Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
    J Clin Invest 119:1571-82. 2009
    ..Together, the results suggest that assessment of TGF-beta signaling pathway status may further stratify the prognosis of ER-positive patients and provide novel therapeutic approaches in the management of breast cancer...
  11. ncbi Evolution of clinical trials in head and neck cancer
    Eddy S Yang
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    Crit Rev Oncol Hematol 71:29-42. 2009
    ..Emerging new technologies such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) will also be reviewed. Functional assessments and quality of life issues will be addressed...
  12. ncbi Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
    ..Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC...
  13. ncbi Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Res 66:8210-8. 2006
    ..The 75-gene list can be used as a prognostic biomarker of recurrence, and our data suggest that the molecular determinants of EMT and NF-kappaB activation can be targeted as the novel therapy in the identified high-risk patients...
  14. ncbi Gene expression profiles as markers of aggressive disease-EGFR as a factor
    Christine H Chung
    Department of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA
    Int J Radiat Oncol Biol Phys 69:S102-5. 2007
  15. ncbi Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
    Elana J Fertig
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    BMC Genomics 13:160. 2012
    ....
  16. ncbi Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer
    Jessica L Baumann
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Cancer Epidemiol 36:e33-9. 2012
    ..This finding suggests that mutation frequency of microsatellite mutations in buccal cells may not be a promising biomarker for lung cancer risk...
  17. ncbi Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 33:1804-8. 2011
    ..Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R])...
  18. ncbi Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma
    Robbert J C Slebos
    Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA
    Clin Cancer Res 12:701-9. 2006
    ..These properties may be exploited as a target of novel therapeutic agents in HNSCC treatment...
  19. ncbi Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer
    Emily Chan
    Vanderbilt University Medical Center, Department of Veterans Affairs, Nashville, TN, USA
    Am J Clin Oncol 34:581-6. 2011
    ..This study explores the clinical and biological effects of combined blockade of these pathways...
  20. ncbi Update on molecular diagnostic tests in head and neck cancer
    Kevin T Palka
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Semin Oncol 35:198-210. 2008
    ....
  21. ncbi Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling
    Ming Li
    Department of Biostatistics, Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 8575, USA
    J Proteome Res 9:4295-305. 2010
    ....
  22. ncbi Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307 USA
    Clin Cancer Res 15:6758-62. 2009
    ..Further understanding of carcinogenesis and clinical behavior of HPV-positive cancers will improve disease prevention, patient care, and surveillance strategies for HNSCC patients...
  23. ncbi Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma
    Hatim Husain
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Laryngoscope 122:2762-8. 2012
    ..Epidermal growth factor receptor (EGFR) and p16 (a surrogate marker of human papillomavirus [HPV] infection) expression are strong prognostic factors in patients with head and neck squamous cell carcinoma (HNSCC)...
  24. ncbi Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
    Ana Markovic
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Expert Rev Anticancer Ther 12:1149-59. 2012
    ....
  25. ncbi Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation
    Barbara A Murphy
    Department of Medicine, Vanderbilt University Medical Center, USA
    Head Neck 32:26-37. 2010
    ....
  26. ncbi Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab
    Shizhen Emily Wang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 28:5605-20. 2008
    ....
  27. ncbi Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee, USA
    Oncology (Williston Park) 23:14-7. 2009
    ..The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed...
  28. ncbi Human papillomavirus in early laryngeal carcinoma
    Jessica L Baumann
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6350, USA
    Laryngoscope 119:1531-7. 2009
    ..To examine the role of HPV status in the etiology, prognosis, and treatment of head and neck squamous cell carcinoma in early larynx malignancies...
  29. ncbi New promising molecular targets in head and neck squamous cell carcinoma
    Julie E Bauman
    Division of Hematology Oncology, Department of Internal Medicine, University of New Mexico Cancer Center, Albuquerque, New Mexico, USA
    Curr Opin Oncol 24:235-42. 2012
    ..This review highlights promising targets with the potential to improve clinical outcomes in HNSCC...
  30. ncbi Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Oncologist 13:725-32. 2008
    ..Considering the heterogeneity of infusion reactions, clinicians need to recognize the underlying nature of these events in order to identify patients at risk as well as provide optimal prophylactic measures and management of symptoms...
  31. ncbi Clinical applications of genomics in head and neck cancer
    Christine H Chung
    Division of Hematology/Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2559, USA
    Head Neck 28:360-8. 2006
    ..In this review, we will discuss advances, limitations and future directions of genomics as it applies to HNSCC...
  32. ncbi A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009
    ....
  33. ncbi Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA
    N Engl J Med 358:1109-17. 2008
    ..A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States...
  34. ncbi Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
    D Neil Hayes
    University of North Carolina Lineberger Comprehensive Cancer Center, School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 18:2056-65. 2012
    ..A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC)...
  35. ncbi Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma
    Hiromitsu Hatakeyama
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 5:e12702. 2010
    ....
  36. ncbi Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy
    Atul Bedi
    Head and Neck Cancer Research Division, Department of Otolaryngology Head and Neck Surgery, 1550 Orleans Street, Johns Hopkins University School of Medicine, Cancer Research Building II, Baltimore, MD 21231, USA
    Mol Cancer Ther 11:2429-39. 2012
    ....
  37. ncbi Biology of human papillomavirus-related oropharyngeal cancer
    Jason D Howard
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Semin Radiat Oncol 22:187-93. 2012
    ....
  38. ncbi Genomics and proteomics: emerging technologies in clinical cancer research
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Crit Rev Oncol Hematol 61:1-25. 2007
    ..We will present a framework for future directions of these technologies and how we believe they should be applied in clinical studies...
  39. ncbi Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation
    Jason D Howard
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, United States
    Oral Oncol 48:10-7. 2012
    ..All treatment modalities are subject to mechanisms of resistance; thus, lessons learned from HNSCC investigations and studies of similar targeted agents in other pertinent malignancies will be discussed...
  40. ncbi A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer
    Zengliu Su
    Vanderbilt Ingram Cancer Center, the Department of Medicine Division of Hematology Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    J Mol Diagn 13:74-84. 2011
    ..56% to 12.5% and 1.56% to 6.25% of the total DNA, respectively. These robust, reliable, and relatively inexpensive assays should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer...
  41. ncbi Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
    Christine H Chung
    Division of Hematology/Oncology, Department of Medicine, Vanderbuilt-Ingram Cancer Center, Vanderbuilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 5:489-500. 2004
    ..This work represents an important step toward the identification of clinically significant biomarkers for HNSCC...